Rhenman & Partners Asset Management Ab View Ray, Inc. Transaction History

Rhenman & Partners Asset Management Ab

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$2.42 - $4.05 $641,300 - $1.07 Million	265,000 Added 36.05%	1,000,000 $2.65 Million
Q1 2022 May 13, 2022	SELL	$3.45 - $5.83 $138,000 - $233,200	-40,000 Reduced 5.16%	735,000 $2.88 Million
Q2 2020 Jul 16, 2020	SELL	$1.66 - $2.73 $124,500 - $204,750	-75,000 Reduced 8.82%	775,000 $1.74 Million
Q1 2020 Apr 16, 2020	BUY	$1.35 - $4.05 $135,000 - $405,000	100,000 Added 13.33%	850,000 $2.13 Million
Q4 2019 Jan 17, 2020	BUY	$2.3 - $4.6 $263,501 - $527,003	114,566 Added 18.03%	750,000 $3.17 Million
Q3 2019 Oct 16, 2019	SELL	$2.9 - $9.56 $82,908 - $273,310	-28,589 Reduced 4.31%	635,434 $1.84 Million
Q4 2018 Feb 05, 2019	BUY	$5.04 - $10.28 $742,896 - $1.52 Million	147,400 Added 28.53%	664,023 $4.03 Million
Q2 2018 Jul 20, 2018	BUY	$6.21 - $8.21 $1.14 Million - $1.51 Million	184,238 Added 55.43%	516,623 $3.58 Million
Q1 2018 Apr 11, 2018	BUY	$6.26 - $10.12 $313,000 - $505,999	50,000 Added 17.71%	332,385 $2.14 Million
Q4 2017 Jan 19, 2018	BUY	$5.6 - $9.9 $1.58 Million - $2.8 Million	282,385	282,385 $2.62 Million

645K

50K

30K

Ticker VRAY
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 181,010,000
Market Cap $1.81M
Description
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin tox...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.